These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25228550)

  • 21. Targeted Therapy in Hematological Malignancies: From Basic Research to Clinical Practice.
    Ma H; Mallampati S; An G; Wang J
    Biomed Res Int; 2015; 2015():157570. PubMed ID: 26436085
    [No Abstract]   [Full Text] [Related]  

  • 22. Dendritic cell count in the graft predicts relapse in patients with hematologic malignancies undergoing an HLA-matched related allogeneic peripheral blood stem cell transplant.
    Rajasekar R; Lakshmi KM; George B; Viswabandya A; Thirugnanam R; Abraham A; Chandy M; Srivastava A; Mathews V
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):854-60. PubMed ID: 20138229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 24. Peer and romantic relationships among adolescent and young adult survivors of childhood hematological cancer: a review of challenges and positive outcomes.
    Foster RH; Stern M
    Acta Haematol; 2014; 132(3-4):375-82. PubMed ID: 25228563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fertility preservation in young females with hematological malignancies.
    Shapira M; Raanani H; Cohen Y; Meirow D
    Acta Haematol; 2014; 132(3-4):400-13. PubMed ID: 25228566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
    Rancea M; Skoetz N; Monsef I; Hübel K; Engert A; Bauer K
    J Natl Cancer Inst; 2012 Jul; 104(14):NP. PubMed ID: 22825560
    [No Abstract]   [Full Text] [Related]  

  • 27. Revisiting the role of dose intensity in hematological malignancies.
    Holmberg LA; Stewart FM
    Exp Hematol; 2006 Jul; 34(7):811-25. PubMed ID: 16797408
    [No Abstract]   [Full Text] [Related]  

  • 28. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Bohlius J; Trelle S; Engert A
    J Natl Cancer Inst; 2005 Apr; 97(7):E1. PubMed ID: 15812063
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
    Ravandi F; Pigneux A; DeAngelo DJ; Raffoux E; Delaunay J; Thomas X; Kadia T; Kantarjian H; Scheuenpflug J; Zhao C; Guo W; Smith BD
    Blood Cancer J; 2015 Dec; 5(12):e375. PubMed ID: 26657199
    [No Abstract]   [Full Text] [Related]  

  • 32. Arsenic derivatives as therapeutic agents for hematologic malignancies.
    Verstovsek S; Estrov Z
    Leuk Res; 2004 Sep; 28(9):901-3. PubMed ID: 15234564
    [No Abstract]   [Full Text] [Related]  

  • 33. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi).
    Sacchi S; Russo D; Avvisati G; Dastoli G; Lazzarino M; Pelicci PG; Bonora MR; Visani G; Grassi C; Iacona I; Luzzi L; Vanzanelli P
    Haematologica; 1997; 82(1):106-21. PubMed ID: 9107096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging targets for hematological malignancies.
    Cilloni D; Frassoni F; Saglio G
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Additional karyotypic abnormalities analysis in patients with hematological malignancies post-allogeneic hematopoietic stem cell transplantation].
    Zhao JW; Zhai WH; Li CW; Zhang Q; Xu FY; Chen HH; Yue JY; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):619-22. PubMed ID: 23134853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan.
    Kai S; Wake A; Okada M; Kurata M; Atsuta Y; Ishikawa J; Nakamae H; Aotsuka N; Kasai M; Misawa M; Taniguchi S; Kato S
    Biol Blood Marrow Transplant; 2013 May; 19(5):812-9. PubMed ID: 23416856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of fludarabine in hematological malignancies.
    Montillo M; Ricci F; Tedeschi A
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].
    Sun ZM; Liu HL; Geng LQ; Zhou CY; Wang XB; Ding KY; Tong J; Zhu WB; Liu X; Wang ZY
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1660-4. PubMed ID: 22944153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New and emerging drug targets for the treatment of hematological malignancies.
    Bendall LJ
    Curr Drug Targets; 2010 Jul; 11(7):767-8. PubMed ID: 20370651
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recent research progress of rhythmic chemotherapy in patients with hematological neoplasm].
    Yu M; Zhou F; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):281-3. PubMed ID: 21569717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.